Shield Therapeutics’ (STX) Buy Rating Reaffirmed at Peel Hunt

Peel Hunt restated their buy rating on shares of Shield Therapeutics (LON:STX) in a research report sent to investors on Thursday morning, ThisIsMoney.Co.Uk reports.

Several other equities research analysts also recently issued reports on STX. FinnCap reiterated a corporate rating on shares of Shield Therapeutics in a research note on Wednesday, October 23rd. Peel Hunt reissued a buy rating and issued a GBX 200 ($2.61) price objective on shares of Shield Therapeutics in a research report on Wednesday, October 2nd.

LON STX opened at GBX 190.50 ($2.49) on Thursday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 4.57 and a current ratio of 4.79. Shield Therapeutics has a one year low of GBX 30 ($0.39) and a one year high of GBX 202 ($2.64). The company’s 50 day moving average price is GBX 184.44 and its 200 day moving average price is GBX 153.58. The firm has a market capitalization of $223.25 million and a price-to-earnings ratio of 52.92.

About Shield Therapeutics

Shield Therapeutics plc, a specialty pharmaceutical company, in the development and commercialization of hospital-focused pharmaceuticals to treat unmet medical needs. Its lead product is Feraccru, a novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease.

Featured Story: Stock Symbols and CUSIP Explained

Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.